Related Experiment Video
Updated: Mar 17, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.7K
2'-Chlorodeoxyadenosine Effectively Induces Complete Remission in Hairy Cell Leukaemia.
P Jacobs1, L Wood1, E P Mansvelt2
1a The Department of Haematology and the Bone Marrow Transplantation Unit , Constantiaberg Medi-Clinic , Burnham Road, Plumstead 7800 , Cape Town , South Africa.
Hematology (Amsterdam, Netherlands)
|July 19, 2016
Summary
2'chlorodeoxyadenosine (2-CDA) offers an effective first-line treatment for Hairy Cell Leukaemia, achieving rapid hematologic recovery and durable remissions in most patients. This purine analogue demonstrates excellent safety and patient acceptability, making it a recommended therapy.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Hairy cell leukaemia (HCL) is an indolent lymphoproliferative disorder with characteristic pancytopenia and monocytopenia.
- Conventional chemotherapy and splenectomy have shown limited efficacy in HCL.
- Interferon therapy has significant side effects and high costs, limiting its use.
Purpose of the Study:
- To evaluate the efficacy and safety of 2'chlorodeoxyadenosine (2-CDA) as a first-line treatment for Hairy Cell Leukaemia.
- To document the long-term outcomes of HCL patients treated with 2-CDA.
Main Methods:
- Retrospective analysis of seventeen consecutive HCL patients treated with 2-CDA over five years.
- Thirteen patients received a standard seven-day course of 0.1 mg/kg 2-CDA via continuous intravenous infusion.
- Peripheral blood counts and marrow biopsies were assessed for response and complications.
Main Results:
- All thirteen treated patients achieved a prompt hematologic response.
- Rapid normalization of peripheral blood counts and marrow morphology was observed.
- Minimal complications, primarily transient leucopenia, were reported. Long-term remission was maintained in most patients, with one relapse at two years.
Conclusions:
- 2'chlorodeoxyadenosine (2-CDA) is a highly effective and safe first-line treatment for Hairy Cell Leukaemia.
- Durable clinical and hematologic remissions are achievable with 2-CDA, with excellent patient acceptability.
- 2-CDA should be considered the standard first-line therapy for HCL globally, including in South Africa.
